Therefore, the significance and value of neoadjuvant chemotherapy in HER2-low-expressing breast cancers still needs to be further explored, and it is unclear whether this population can receive the maximum benefit from neoadjuvant chemotherapy (34). Here, ERBB2 is linked to breast carcinoma.